Oblique Therapeutics has received a grant from Vinnova

Oblique Therapeutics has received a grant from the Vinnova future biological medicines program to develop functional antibodies against TRPV1 and TRPV2 for inflammatory/idiopathic pain and metastatic cancer, respectively.